We are live on !
Find out more
Vestal Point Capital Portfolio holdings
AUM
$4.28B
Turnover
40.4%
1-Year Est. Return
239%
This Fund
S&P 500
This Quarter Est. Return
+17.74%
1 Year Est. Return
+239%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.28B
AUM Growth
+$703M
(+20%)
Cap. Flow
+$110M
Cap. Flow % of AUM
Cap. Flow %
2.57%
Top 10 Holdings %
Top 10 Hldgs %
50.29%
Holding
99
New
9
Increased
31
Reduced
22
Closed
31
Avg Time Held
0.8
years
Top 10 Avg Time Held
0.3
years
Top 20 Avg Time Held
0.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
United Therapeutics
UTHR
|
+$203M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$134M |
| 3 |
Abbott
ABT
|
+$128M |
| 4 |
Zimmer Biomet
ZBH
|
+$106M |
| 5 |
Insulet
PODD
|
+$103M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$281M |
| 2 |
Apogee Therapeutics
APGE
|
+$92.6M |
| 3 |
Scholar Rock
SRRK
|
+$65.1M |
| 4 |
Repligen
RGEN
|
+$64.5M |
| 5 |
Vera Therapeutics
VERA
|
+$55M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
BioMarin Pharmaceuticals
BMRN
$10.8B
| $345M | 8.06% |
6,025,000
+2,450,000
| +69% | +$134M |
2025 Q2
4 quarters
|
|
2
Neurocrine Biosciences
NBIX
$14.8B
| $317M | 7.4% |
1,880,000
+630,000
| +50% | +$93.5M |
2026 Q1
1 quarter
|
|
3
Abivax
ABVX
$7.55B
| $313M | 7.32% |
2,349,443
+849,443
| +57% | +$96.1M |
2025 Q3
3 quarters
|
|
|
4
United Therapeutics
UTHR
$25.4B
| $236M | 5.51% |
435,000
+360,000
| +480% | +$203M |
2026 Q1
1 quarter
|
|
5
Enliven Therapeutics
ELVN
$3.04B
| $203M | 4.74% |
4,000,000
+750,000
| +23% | +$31.8M |
2025 Q2
4 quarters
|
|
6
Nurix Therapeutics
NRIX
$2.79B
| $195M | 4.56% |
8,050,000
+1,550,000
| +24% | +$26.4M |
2024 Q2
8 quarters
|
|
7
Bicara Therapeutics
BCAX
$1.12B
| $156M | 3.64% |
5,250,000
-175,000
| -3% | -$3.91M |
2024 Q3
7 quarters
|
|
8
Taysha Gene Therapies
TSHA
$1.31B
| $132M | 3.09% |
19,415,000
+1,415,000
| +8% | +$8.37M |
2025 Q2
4 quarters
|
|
9
Arrowhead Research
ARWR
$8.33B
| $128M | 3% |
1,575,000
-700,000
| -31% | -$51.7M |
2025 Q4
2 quarters
|
|
|
10
Abbott
ABT
$181B
| $127M | 2.97% |
+1,400,000
| New | +$128M |
2026 Q2
0 quarters
|
|
|
11
Zimmer Biomet
ZBH
$18.6B
| $121M | 2.82% |
1,400,000
+1,210,000
| +637% | +$106M |
2025 Q4
2 quarters
|
|
12
Disc Medicine
IRON
$3.45B
| $113M | 2.65% |
1,550,000
+850,000
| +121% | +$58.4M |
2025 Q2
4 quarters
|
|
13
Monte Rosa Therapeutics
GLUE
$894M
| $111M | 2.6% |
4,600,000
+996,535
| +28% | +$18.8M |
2025 Q3
3 quarters
|
|
|
14
Insulet
PODD
$10.4B
| $102M | 2.38% |
670,000
+619,399
| +1,224% | +$103M |
2026 Q1
1 quarter
|
|
15
Ascendis Pharma A/S
ASND
$16.1B
| $100M | 2.34% |
375,000
| – | – |
2023 Q4
10 quarters
|
|
16
AstraZeneca
AZN
$267B
| $85.3M | 1.99% |
450,000
+350,000
| +350% | +$65.8M |
2026 Q1
1 quarter
|
|
17
Sanofi
SNY
$100B
| $85.3M | 1.99% |
2,000,000
+600,000
| +43% | +$26.8M |
2026 Q1
1 quarter
|
|
|
18
Revolution Medicines
RVMD
$39.4B
| $84.3M | 1.97% |
450,000
-1,925,000
| -81% | -$281M |
2025 Q2
4 quarters
|
|
19
BioCryst Pharmaceuticals
BCRX
$2.01B
| $83M | 1.94% |
8,300,000
+1,275,000
| +18% | +$11.5M |
2025 Q4
2 quarters
|
|
20
Dyne Therapeutics
DYN
$2.94B
| $75M | 1.75% |
3,375,000
-625,000
| -16% | -$11.6M |
2025 Q1
5 quarters
|
|
21
Nektar Therapeutics
NKTR
$1.28B
| $69.8M | 1.63% |
1,000,000
+715,000
| +251% | +$52.3M |
2026 Q1
1 quarter
|
|
22
Globus Medical
GMED
$11B
| $67.2M | 1.57% |
850,000
+239,480
| +39% | +$20.4M |
2024 Q4
6 quarters
|
|
23
Tarsus Pharmaceuticals
TARS
$3.28B
| $66.1M | 1.54% |
1,050,000
+850,000
| +425% | +$54.3M |
2026 Q1
1 quarter
|
|
24
Immatics
IMTX
$1.09B
| $62.6M | 1.46% |
6,175,000
| – | – |
2023 Q4
10 quarters
|
|
25
Trevi Therapeutics
TRVI
$1.78B
| $57.8M | 1.35% |
3,100,000
+933,496
| +43% | +$13.6M |
2026 Q1
1 quarter
|
|
Similar funds
Vestal Point Capital's Q2 2026 Portfolio in Review
As of Q2 2026, Vestal Point Capital held 99 positions worth $4.28B, up 20% from $3.58B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Vestal Point Capital's Q2 2026 filing shows 9 new, 31 increased, 22 reduced and 31 closed positions. Its largest new stake was Abbott: 1,400,000 shares worth $127M. The largest sale was Revolution Medicines, an estimated $281M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Vestal Point Capital's largest Q2 2026 buy was Abbott: 1,400,000 shares worth $127M.
- Vestal Point Capital added most to United Therapeutics in Q2 2026, an estimated $203M increase.
- Vestal Point Capital's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $281M.
- Vestal Point Capital fully exited Apogee Therapeutics in Q2 2026, selling an estimated $92.6M.
- Vestal Point Capital's ten largest holdings make up 50% of its $4.28B portfolio in Q2 2026.
- Vestal Point Capital opened 9 new positions and closed 31 in Q2 2026.
- Vestal Point Capital's portfolio value rose 20% quarter-over-quarter to $4.28B.
Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.